Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lorigerlimab
- Development stage
- Phase 2
- Lead developer
- MacroGenics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lorigerlimab is an investigational, bispecific monoclonal antibody designed to target both programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) on tumor-infiltrating lymphocytes. By binding to these immune checkpoint proteins, lorigerlimab inhibits their mediated downregulation of T-cell activation and proliferation, thereby enhancing antitumor immune responses. The drug is based on MacroGenics' DART (Dual-Affinity ReTargeting) platform and is being developed primarily for the treatment of metastatic castration-resistant prostate cancer (mCRPC), with additional studies in solid tumors. Lorigerlimab has demonstrated a manageable safety profile and encouraging antitumor activity in early-phase clinical trials.
- Other names
- PD-1 x CTLA-4 bispecific DART moleculePD1 x CTLA-4 bispecific DART moleculePD 1 x CTLA-4 bispecific DART molecule
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on lorigerlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lorigerlimab.